@article{ref1,
title="Use of medical cannabis to treat traumatic brain injury",
journal="Journal of neurotrauma",
year="2020",
author="Hergert, Danielle Cara and Robertson-Benta, Cidney and Sicard, Veronik and Schwotzer, Daniela and Hutchison, Kent and Covey, Dan P. and Quinn, Davin and Sadek, Joseph R. and McDonald, Jacob and Mayer, Andrew",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="There is not a single pharmacological agent with demonstrated therapeutic efficacy  for traumatic brain injury (TBI). With recent legalization efforts and the growing  popularity of medical cannabis, patients with TBI will inevitably consider medical  cannabis as a treatment option. Preclinical TBI research suggests cannabinoids have  neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis  use has consistently shown to have detrimental effects. Our review identified a  paucity of high-quality studies examining the beneficial and adverse effects of  medical cannabis on traumatic brain injury, with only a single Phase III randomized  control trial. However, observational studies demonstrate that TBI patients are  using medical and recreational cannabis to treat their symptoms, highlighting  inconsistencies between public policy, perception of potential efficacy, and the  dearth of empirical evidence. We conclude that randomized controlled trials and  prospective studies with appropriate control groups are necessary to fully  understand the efficacy and potential adverse effects of medical cannabis for TBI.<p /> <p>Language: en</p>",
language="en",
issn="0897-7151",
doi="10.1089/neu.2020.7148",
url="http://dx.doi.org/10.1089/neu.2020.7148"
}